Portal hypertension (an increase in blood pressure in the portal vein that carries the blood
from the intestine and spleen to the liver) underlies most of the serious complications of
liver cirrhosis. This randomised placebo controlled study in people with liver cirrhosis
evaluates the acute effects serelaxin (RLX030) infusion on portal hypertension and liver
blood flow.